# Mammoth Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/mammoth-biosciences

- Industry: Biotechnology
- Headquarters: Brisbane, US
- Website: www.mammoth.bio
- Total disclosed funding: $268M
- Latest round: Series D (Jul 22, 2021)
- Investors on record: 16

## About

Based in California, US, and founded in 2017 by Ashley Tehranchi, Janice Chen, Jennifer Doudna, Lucas Harrington, and Trevor Martin, Mammoth Biosciences Inc. (Mammoth) operates as a biotechnology company that develops the CRISPR-based detection platform that is capable of sensing any biomarker or disease with DNA/RNA. As of September 2021, Mammoth Biosciences has over 100 employees. In September 2021, the company received USD 150 million from  Redmile Group, with participation from Foresite Capital, Senator Investment Group, Sixth Street, Greenspring Associates, Mayfield, Decheng Capital, and others.

The company offers CRISPR-based therapeutics products and diagnostics to cure and detect a wide range of diseases intended to help medical professionals to improve the diagnostics process of disease detection.

Mammoth Biosciences Inc. will use the September 2021 funding to expand its toolkit of next-generation CRISPR systems with a focus on building permanent genetic cures through in vivo gene-editing therapeutics and democratizing disease detection with on-demand diagnostics.

## Funding rounds

- Series D, Jul 22, 2021, $150M — Mayfield Fund, Greenspring Associates, Foresite Capital, Redmile Group, Decheng Capital, Plum Alley, NFX, Senator Investment Group, Sixth Street
- Series C, May 19, 2020, $50M — Foresite Capital, Redmile Group, NFX, Amazon
- Series B, Jan 30, 2020, $45M — Mayfield Fund, Decheng Capital, Plum Alley, NFX, Verily Life Sciences LLC, aMoon, Pacific 8 Ventures
- Series A, Jul 31, 2018, $23M — Mayfield Fund, 8VC, NFX, Kairos, Tectonic Capital
- Seed, May 26, 2018 — Kairos

## Investors

- Kairos (https://capitalatlas.ai/funds/kairos) — Seed, Series A
- Mayfield Fund (https://capitalatlas.ai/funds/mayfield-fund) — Series A, Series B, Series D
- 8VC (https://capitalatlas.ai/funds/8vc) — Series A
- NFX (https://capitalatlas.ai/funds/nfx) — Series A, Series B, Series C, Series D
- Tectonic Capital (https://capitalatlas.ai/funds/tectonic-capital) — Series A
- Decheng Capital (https://capitalatlas.ai/funds/decheng-capital) — Series B, Series D
- Plum Alley (https://capitalatlas.ai/funds/plum-alley) — Series B, Series D
- Verily Life Sciences LLC — Series B
- aMoon (https://capitalatlas.ai/funds/amoon) — Series B
- Pacific 8 Ventures — Series B
- Foresite Capital (https://capitalatlas.ai/funds/foresite-capital) — Series C, Series D
- Redmile Group (https://capitalatlas.ai/funds/redmile-group) — Series C, Series D
- Amazon (https://capitalatlas.ai/funds/amazon) — Series C
- Greenspring Associates (https://capitalatlas.ai/funds/greenspring-associates) — Series D
- Senator Investment Group (https://capitalatlas.ai/funds/senator-investment-group) — Series D
- Sixth Street (https://capitalatlas.ai/funds/sixth-street) — Series D